MediView and GE Healthcare to Bring Augmented Reality Solutions to Medical Imaging for the Interventional Space – Yahoo Finance

New collaboration seeks to advance precision care through intuitive visualization, remote collaboration and evidence-based insights.
CHICAGO, November 28, 2022–(BUSINESS WIRE)–GE Healthcare, a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, and MediView XR, Inc., a leading clinical augmented reality med-tech company, announced today their collaboration to integrate medical imaging into mixed reality solutions through the development of the OmnifyXR™ Interventional Suite System.¹ MediView’s current technology platform leverages spatial computing and mixed reality, united with medical imaging in combining augmented reality visualization, seamless remote collaboration and evidence-based clinical insights.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005691/en/
MediView and GE Healthcare to bring augmented reality solutions to medical imaging for the interventional space (Photo: Business Wire)
“We are thrilled to advance our strategic collaboration with GE Healthcare by co-developing and creating the interventional suite of the future – one that is designed to improve ergonomics, with natural interactions for optimized workflow and facilitates care team collaboration. The physician is empowered to simultaneously interface with virtual monitors, holographic 3D anatomy, and remotely collaborate with colleagues around the world,” said Mina Fahim, President and CEO of MediView. “Utilizing GE Healthcare’s exceptional imaging and MediView’s expertise in real-time augmented reality visualization and navigation, we’re proud to together launch one of the largest deployments of augmented reality in healthcare to-date and grow clinical adoption of innovative extended reality solutions.”
The collaboration between the two organizations brings together MediView’s expertise in 3D augmented reality medical visualization, surgical navigation, telecollaboration capabilities and procedural data insights to enhance and simplify clinical decision making along with GE Healthcare’s superb interventional imaging technologies, digital infrastructure, data analytics, and clinical decision support capabilities.
“Augmented reality in imaging is key to improved visualization of anatomy and enhanced user experience. Our collaboration with MediView demonstrates our commitment to advancing the delivery of precision care by expanding the capabilities of our own imaging guided systems through an open architecture and the integration of promising and complementary technologies, like OmnifyXR Interventional Suite, into clinical workflow. Together, we can help clinicians use image guidance technologies to their full potential in order to help in the delivery of high-quality patient care,” said Arnaud Marie – General Manager for Global Interventional at GE Healthcare.
There is a growing focus on streamlining and optimizing clinical workflows and enhancing ergonomics among clinicians utilizing medical imaging. The OmnifyXR solution provides a heads-up, augmented reality display of interventional x-ray imaging systems using Microsoft’s latest HoloLens technology. The solution integrates multiple holographic displays of live imaging to help improve ergonomics regardless of working position and features 3D volume for improved anatomy visualization to help clinicians better assess complex anatomies and inform clinical decision making. The solution also features remote collaboration, enabling clinicians to partner from a distance, train, proctor and facilitate collaborative care.
GE Healthcare and MediView will co-market the solution and will explore opportunities for joint go-to-market efforts, with an initial market launch in the US and global expansion planned for the future.
Find out more at RSNA by visiting GE Healthcare in the North Hall – #7324. Click here more details.
About MediView:
MediView is a Cleveland, OH based med-tech company that is working to advance human health through its digital augmented reality ecosystem. MediView’s intuitive augmented reality visualization platform aims to unlock the full potential of 3D data to transform image guided medical procedures with intuitive 3D X-ray vision visualization, seamless remote collaboration, and evidence-based data insights. Currently, MediView is delivering these technologies through partnerships with leading organizations GE Healthcare and Microsoft.
To learn more, visit www.mediview.com.
About GE Healthcare:
GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 48,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.
Follow us on Facebook, LinkedIn, Twitter, Instagram and Insights for the latest news, or visit our website www.gehealthcare.com for more information.
¹ OmnifyXR Interventional Suite does not require a 510(k) and is not yet available for sale. Not yet CE marked. May not be marketed or placed into service in the EU until it has been made to comply with CE marking. OmnifyXR™ Interventional Suite is designed and manufactured by MediView XR, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221128005691/en/
Contacts
MediView
Amy Ho | amy.ho@mediview.com

GE Healthcare
Emily Niles | Emily.niles@ge.com
Related Quotes
Stock futures gain as markets track China Covid changes; President Biden urges Congress to intervene in rail strike; Disney shares gain after first town hall since Bob Iger's return; Cyber Monday sales hit record as shoppers seek bargains and UnitedHealth dips on muted 2023 profit forecast.
Zacks.com users have recently been watching Nike (NKE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Nike (NKE) closed the most recent trading day at $104.96, moving -0.94% from the previous trading session.
Best Chinese stocks. China Covid cases are at record highs, but lockdown protests are spreading almost as fast.
With healthy fundamentals and upward estimate revisions, Cambium (CMBM) appears to be an enticing investment option at the moment.
WASHINGTON (Reuters) -The U.S. Federal Trade Commission and seven U.S. states reached a settlement with Alphabet Inc's Google and iHeartMedia Inc over allegations of deceptive ads promoting Google's Pixel 4 smartphone, the FTC said. The FTC said in a statement on Monday that the companies aired nearly 29,000 deceptive endorsements by radio personalities promoting their use of and experience with Google's Pixel 4 phone in 2019 and 2020. The allegations were settled by the companies, who agreed to pay $9.4 million in penalties, the FTC said.
Dow Jones futures were higher ahead of Tuesday's open after the Dow Jones Industrial Average sold off nearly 500 points Monday.
Homicide officials are investigating the fatal shooting of a Victorville man in the mountain community of Fawnskin near Big Bear Lake.
CEO Joth Ricci will get help in running Dutch Bros Inc. come the new year. The Grants Pass-based drive-through beverage purveyor on Monday said Christine Barone would join it as president in the first quarter of 2023, reporting to Ricci and focusing on operations. Ricci has been Dutch Bros CEO since early 2021, when he took over from founder Travis Boersma, and president since coming to the company two years before that.
What happened Shares of Anavex Life Sciences (NASDAQ: AVXL), a clinical-stage biotech that specializes in therapies to treat neurodegenerative and neurodevelopmental diseases, fell by 23.5% on Monday.
The dispute between the world's richest man and the world's biggest corporation spills into the open.
Eisai plans to share additional data about the Alzheimer’s disease treatment it's developing with Biogen this week.
(Bloomberg) — Amazon.com Inc.’s cloud-computing unit is rolling out new chips designed to power the highest-end of computing, supporting tasks such as weather forecasting and gene sequencing.Most Read from BloombergApple to Lose 6 Million iPhone Pros From Tumult at China PlantNext Covid-19 Strain May be More Dangerous, Lab Study ShowsStocks Hit by Fedspeak as China Woes Boost Havens: Markets WrapThere’s a Job-Market Riddle at the Heart of the Next RecessionAmazon Web Services, the largest provi
Dogecoin surged over 27% in the past week amidst speculation that Elon Musk and Ethereum's Vitalik Buterin are working on an upgrade for the dog-faced memecoin.
(Bloomberg) — Elon Musk’s tumultuous month atop Twitter Inc. has already included firing most of the company’s employees, tinkering with key features and restoring banned accounts. Now he’s embarking on what could be his riskiest gambit yet: a war with Apple Inc.Most Read from BloombergApple to Lose 6 Million iPhone Pros From Tumult at China PlantNext Covid-19 Strain May be More Dangerous, Lab Study ShowsStocks Hit by Fedspeak as China Woes Boost Havens: Markets WrapThere’s a Job-Market Riddle
In this article, we will take a look at 15 most valuable telecom companies in the world. If you want to see more of the most valuable telecom companies in the world, go directly to 5 Most Valuable Telecom Companies In The World. Telecom companies, otherwise known as telecommunication companies, are companies that allow their […]
Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher.
Axsome Therapeutics Inc's (NASDAQ: AXSM) AXS-05 substantially and statistically significantly delayed the time to relapse and prevented relapse of agitation in patients with Alzheimer's disease, compared to placebo. The ACCORD Phase 3 trial represented a 3.6-fold lower relapse risk than the placebo. AXS-05 also met the key secondary endpoint of relapse prevention based on the relapse rates during the double-blind treatment period (7.5% of AXS-05 patients vs. 25.9% of placebo patients). Related:
The best 5G stocks to invest in will change as smartphone apps, enterprise services and the metaverse develop over time.
(Bloomberg) — Eisai Co shares fell the most in about 16 months following a report of a second death potentially linked to the groundbreaking experimental drug for Alzheimer’s disease it’s developing with Biogen Inc.Most Read from BloombergApple to Lose 6 Million iPhone Pros From Tumult at China PlantNext Covid-19 Strain May be More Dangerous, Lab Study ShowsMusk Threatens War With Apple, Jeopardizing Vital RelationshipStocks Hit by Fedspeak as China Woes Boost Havens: Markets WrapThe case invol

source